Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
To evaluate the efficacy and safety of durvalumab in combination with doxorubicin and ifosfamide in patients with PSC.
Carcinoma, Non-Small-Cell Lung
DRUG: Durvalumab + doxorubicin + ifosfamide
Response rate (RR), modified RECIST1.1, a percentage and is calculated by dividing the number of patients who achieved a response (complete or partial) by the total number of evaluable patients in the study, 24 months
Progression-free survival (PFS), the percentage of patients who have not experienced disease progression or death from any cause within 2 years from the start of treatment., 24 months|Overall survival (OS), The duration of time from the start of treatment until death from any cause, 24 months|Adverse event, The number of patients with treatment-related AE as assessed by NCI CTCAE, 24 months
biomarker, Correlation with C-MET mutation, PD-L1 IHC, 24 months
This is a phase II multi-center, open-label study to evaluate the efficacy and safety of durvalumab in combination with doxorubicin and ifosfamide in patients with PSC.